Evidence map›Paper›PMID 33670716›Full record

ArticleBiomolecules2021

Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.

Marion Buffard, Aurélien Naldi, Gilles Freiss, Marcel Deckert, Ovidiu Radulescu, Peter J Coopman, Romain M Larive

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Journal of biosciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marion BuffardIRCM, Université de Montpellier, ICM, INSERM, F-34298 Montpellier, France.
Aurélien NaldiInstitut de Biologie de l'ENS (IBENS), Département de Biologie, École Normale Supérieure, CNRS, INSERM, Université PSL, F-75005 Paris, France.ORCID 0000-0002-6495-2655
Gilles FreissIRCM, Université de Montpellier, ICM, INSERM, F-34298 Montpellier, France.ORCID 0000-0002-1943-0735
Marcel DeckertC3M, Université Côte d'Azur, INSERM, équipe «Microenvironnement, Signalisation et Cancer», F-06204 Nice, France.ORCID 0000-0003-2094-559X
Ovidiu RadulescuLPHI, Université de Montpellier, CNRS, F-34095 Montpellier, France.ORCID 0000-0001-6453-5707
Peter J CoopmanIRCM, Université de Montpellier, ICM, INSERM, F-34298 Montpellier, France.ORCID 0000-0003-3720-523X
Romain M LariveIRCM, Université de Montpellier, ICM, INSERM, F-34298 Montpellier, France.ORCID 0000-0001-8479-209X
Centre National de la Recherche Scientifique · FRInserm · FRÉcole Nationale Supérieure de Chimie de Montpellier · FR

Funding

Agence Nationale de la Recherche ANR-10-LABX-12-01INCa-Cancéropôle Grand Sud-Ouest, Emergence program 2018-E01Institut National Du Cancer 2018-E01Institut National Du Cancer ASC14021FSALabex EpiGenMed, « Investissements d'avenir » program ANR-10-LABX-12-01Ligue Contre le Cancer JPB/GA/MV/39-2019Ligue Régionale Contre le Cancer, Comité du Gard JPB/GA/MV/39-2019Plan Cancer ASC14021FSA
6 · The paper itself

Abstract

Spleen tyrosine kinase (SYK) can behave as an oncogene or a tumor suppressor, depending on the cell and tissue type. As pharmacological SYK inhibitors are currently evaluated in clinical trials, it is important to gain more information on the molecular mechanisms underpinning these opposite roles. To this aim, we reconstructed and compared its signaling networks using phosphoproteomic data from breast cancer and Burkitt lymphoma cell lines where SYK behaves as a tumor suppressor and promoter. Bioinformatic analyses allowed for unveiling the main differences in signaling pathways, network topology and signal propagation from SYK to its potential effectors. In breast cancer cells, the SYK target-enriched signaling pathways included intercellular adhesion and Hippo signaling components that are often linked to tumor suppression. In Burkitt lymphoma cells, the SYK target-enriched signaling pathways included molecules that could play a role in SYK pro-oncogenic function in B-cell lymphomas. Several protein interactions were profoundly rewired in the breast cancer network compared with the Burkitt lymphoma network. These data demonstrate that proteomic profiling combined with mathematical network modeling allows untangling complex pathway interplays and revealing difficult to discern interactions among the SYK pathways that positively and negatively affect tumor formation and progression.

Indexed as

Breast NeoplasmsBurkitt LymphomaCell Line, TumorFemaleHumansMCF-7 CellsModels, TheoreticalPhosphoproteinsProteomicsSignal TransductionSyk KinasePhosphoproteinsSyk KinaseSYK protein, humanbreast cancerBurkitt lymphomaNetwork comparisononcogenephosphoproteomicsSYK signalingtumor suppressor

Identifiers

PMID33670716
PMCPMC7923165
OpenAlexW3130385876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.